⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2634659 | 0.80 | — | — | |
| SCHEMBL3964704 | 0.77 | — | — | |
| SCHEMBL1251785 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL8470162 | 0.66 | — | — | |
| Hydrochloric Acid SCHEMBL941846 | 0.66 | — | — | |
| SCHEMBL5507961 | 0.65 | — | — | |
| Hydrochloric Acid SCHEMBL21327851 | 0.65 | — | — | |
| SCHEMBL545834 | 0.62 | MPO (0.33) | — | |
| SCHEMBL887121 | 0.62 | MPO (0.36) | — | |
| SCHEMBL6536480 | 0.59 | MPO (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115884977-A | Stereoselective preparation of selected purine phosphoramidates | 阿堤亚制药公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20220162603-A1 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | IONIS PHARMACEUTICALS, INC. (US) | 2022-05-26 | — | — | US | disclosed |
| US-11078485-B2 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | IONIS PHARMACEUTICALS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-10266825-B2 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | IONIS PHARMACEUTICALS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170369880-A1 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | IONIS PHARMACEUTICALS, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-9708610-B2 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | IONIS PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| EP-2957568-B1 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | IONIS PHARMACEUTICALS INC (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-1730309-B1 | COMPOSITIONS AND METHODS FOR OPTIMIZING CLEAVAGE OF RNA BY RNASE H | IONIS PHARMACEUTICALS INC (US) | 2016-05-04 | — | — | EP | disclosed |
| US-20160053261-A1 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2016-02-25 | — | — | US | disclosed |
| EP-2957568-A1 | COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION | Isis Pharmaceuticals, Inc. (US) | 2015-12-23 | — | — | EP | disclosed |
| US-20070015722-A1 | Double stranded compositions comprising a 3'-endo modified strand for use in gene modulation | BANK OF AMERICA, N.A. | 2007-01-18 | — | — | US | disclosed |
| US-20060241072-A1 | Oligomeric compounds for use in gene modulation | ISIS PHARMACEUTICALS, INC. | 2006-10-26 | — | — | US | disclosed |
| US-20060084094-A1 | Conjugates for use in hepatocyte free uptake assays | ISIS PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | US | disclosed |
| US-20050260755-A1 | Sequential delivery of oligomeric compounds | ISIS PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050221275-A1 | Hepatocyte free uptake assays | ISIS PHARMACEUTICALS, INC. | 2005-10-06 | — | — | US | disclosed |
| US-20050142581-A1 | Microrna as ligands and target molecules | ISIS PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| US-20050080246-A1 | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation | IONIS PHARMACEUTICALS, INC. | 2005-04-14 | — | — | US | disclosed |
| US-20050074801-A1 | Nucleosides; solid phase synthesis; biochemical conjugation; for lowering cholesterol, triglyceride, plasma leptin, glucose, and/or plasma insulin levels; for lowering body weight | ISIS PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-20050043268-A1 | Inhibition of viruses | MEDICAL RESEARCH COUNCIL (GB) | 2005-02-24 | — | — | US | disclosed |
| US-20050026160-A1 | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation | IONIS PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |